E-cigarette or Vaping Product Use-Associated Lung Injury (EVALI)

EVALI stands for E-cigarette or Vaping Product Use-Associated Lung Injury. It is a condition linked to the use of e-cigarettes or vaping products, which can cause severe lung damage. EVALI was first identified in the United States in 2019 and has since been recognized as a public health concern in several countries.

The exact cause of EVALI is still being studied, but evidence points to harmful chemicals—particularly vitamin E acetate—found in THC-containing vaping products, as well as other toxic substances in e-cigarette liquids and unregulated products. The condition underscores the dangers of vaping, especially with unregulated or counterfeit products.

Looking for online prescriptions?

Starting from $29.90

Request Now

Looking for online prescriptions?

Starting from $29.90

Request Now

Causes of EVALI

The primary cause of EVALI (E-cigarette or Vaping Product Use-Associated Lung Injury) is believed to be the inhalation of harmful substances found in e-cigarettes or vaping products. Several factors contribute to the development of EVALI:

1. Vitamin E Acetate

• Vitamin E acetate, a substance commonly used as a thickening agent in THC (tetrahydrocannabinol) vaping products, has been strongly linked to EVALI cases. When inhaled, it can interfere with lung function and cause serious lung damage.

2. THC Products

• Many EVALI cases have been associated with vaping products that contain THC, the psychoactive compound in marijuana. Contaminants in illegal or unregulated THC vaping products, including vitamin E acetate, are thought to contribute to the injury.

3. Chemical Irritants in E-cigarette Liquids

• Some e-cigarette liquids contain harmful chemicals like diacetyl, a substance linked to "popcorn lung," which damages the airways and causes chronic respiratory issues. These chemicals may cause inflammation and damage when inhaled through vaping.

4. Unregulated or Counterfeit Products

• Vaping products purchased from unreliable or unregulated sources, particularly those containing THC, are more likely to contain harmful additives or contaminants that can cause lung injury. These products may not have been tested for safety or quality.

5. Inhalation of Contaminated Aerosols

• Vaping devices heat liquid into an aerosol that can contain various chemicals, including flavoring agents, propylene glycol, and glycerin. The inhalation of certain additives or impurities in these aerosols may contribute to respiratory issues and lung injury.

6. Lack of Quality Control and Standardization

• Many vaping products, particularly those containing THC, are not subject to the same strict regulations as tobacco products, which increases the risk of contamination with harmful substances.

Common Signs and Symptoms of EVALI

The signs and symptoms of EVALI (E-cigarette or Vaping Product Use-Associated Lung Injury) can vary in severity but typically include a combination of respiratory and systemic (body-wide) symptoms. These symptoms generally develop a few days to weeks after using e-cigarettes or vaping products, especially those containing THC.

1. Respiratory Symptoms:
   • Cough
   • Shortness of breath
   • Chest pain
   • Difficulty breathing
   • Wheezing (a whistling sound when breathing)
   • Fatigue
2. Systemic Symptoms:
   • Fever
   • Chills
   • Nausea and vomiting
   • Diarrhea
   • Unexplained weight loss
3. Other Symptoms:
   • Headache
   • Dizziness
   • Confusion (in severe cases)

Progression:

• Symptoms may worsen rapidly and can lead to serious complications, including respiratory failure or the need for mechanical ventilation.

If you or someone you know experiences any of these symptoms, especially after using e-cigarettes or vaping products, it's important to seek medical attention immediately. Early intervention can help prevent more severe lung damage or other complications.

Diagnosing EVALI

Diagnosing EVALI (E-cigarette or Vaping Product Use-Associated Lung Injury) involves a combination of clinical evaluation, patient history, laboratory tests, and imaging studies. Since EVALI symptoms overlap with those of other respiratory illnesses, it can be challenging to distinguish it from other lung conditions like pneumonia or viral infections. Below is an overview of the diagnostic process for EVALI:

1. Patient History

• Vaping History: The most crucial factor in diagnosing EVALI is a clear history of e-cigarette or vaping product use, particularly the use of products containing THC (tetrahydrocannabinol) or nicotine.
• Timeframe: Symptoms typically develop within a few days to weeks after using vaping products, so asking about recent usage is essential.
• Substances Used: A detailed account of the specific products used (e.g., nicotine, THC, flavored vapes) helps guide the diagnosis, as products with unregulated additives (like vitamin E acetate) are associated with a higher risk of EVALI.

2. Physical Examination

• A healthcare provider will conduct a thorough physical examination, focusing on signs of lung damage, such as:
  • Abnormal breath sounds (wheezing, crackles)
  • Cyanosis (bluish tint to the skin, indicating a lack of oxygen)
  • Respiratory distress or labored breathing

3. Imaging Studies

• Chest X-ray or CT Scan: Imaging tests are essential for assessing lung involvement. The chest X-ray or CT scan may show diffuse lung damage, such as:
  • Ground-glass opacities (areas where the lung tissue is damaged)
  • Pulmonary infiltrates (inflammation or infection in the lungs)
  • Other signs of acute lung injury
• These imaging findings can help rule out other causes of lung damage, such as pneumonia.

4. Laboratory Tests

• Blood Tests: Blood tests may be conducted to check for signs of infection or inflammation, such as elevated white blood cell count or markers of inflammation.
• Arterial Blood Gases (ABGs): These tests can assess the levels of oxygen and carbon dioxide in the blood, which may be abnormal in severe cases of EVALI.
• Urine Tests: These can be used to rule out other potential causes, such as viral infections.

5. Exclusion of Other Conditions

• The diagnosis of EVALI is primarily one of exclusion. Doctors must rule out other possible causes of the symptoms, including:
  • Bacterial or viral pneumonia
  • Asthma or chronic lung diseases
  • Pulmonary embolism
  • Other forms of lung injury or infection

6. Clinical Diagnosis

• A clinical diagnosis of EVALI is made when the following criteria are met:
  • The patient has a history of e-cigarette or vaping product use, especially those containing THC or nicotine.
  • The patient exhibits respiratory symptoms (such as cough, shortness of breath, or chest pain).
  • Imaging shows signs of lung injury, and other causes (e.g., infection, underlying lung disease) are ruled out.
  • No alternative diagnosis adequately explains the patient’s symptoms.

7. Additional Testing

• In some cases, a bronchoscopy (a procedure to visualize the airways and take a sample of lung tissue) may be performed to further assess lung damage or collect samples to test for infections or other abnormalities.

The treatment of EVALI

The treatment of EVALI (E-cigarette or Vaping Product Use-Associated Lung Injury) focuses on managing symptoms, reducing inflammation, and providing respiratory support. Treatment varies based on the severity of the condition and whether the patient has other underlying health issues. In severe cases, hospitalization and intensive care may be required.

1. Hospitalization (for severe cases)

• Many individuals with EVALI, especially those with severe respiratory distress, require hospitalization. In the hospital, healthcare providers can offer more intensive care, including oxygen therapy and mechanical ventilation if needed.

2. Oxygen Therapy

• Oxygen supplementation is commonly used to help patients with difficulty breathing or low blood oxygen levels. This may involve administering oxygen through nasal cannulas, masks, or, in severe cases, mechanical ventilation.

3. Corticosteroids (Steroid Therapy)

• Corticosteroids, such as prednisone, are commonly used to reduce lung inflammation in EVALI patients. Steroids help to decrease the inflammation in the lungs caused by the vaping-related injury and can help improve breathing and lung function.
• In some cases, high-dose corticosteroids may be given intravenously for rapid effect, followed by a tapering dose once symptoms improve.

4. Supportive Care

• Supportive care includes treatments aimed at helping the body heal and manage symptoms. This can include:
  • Hydration: To help maintain blood pressure and support overall health.
  • Antibiotics: While EVALI itself is not caused by infection, antibiotics may be prescribed if there is a secondary bacterial infection or if pneumonia is suspected.

5. Mechanical Ventilation (In Severe Cases)

• In cases of severe respiratory failure, mechanical ventilation (use of a ventilator to assist with breathing) may be necessary to provide adequate oxygen to the body until the lungs heal.

6. Antiviral Treatment (if applicable)

• If a viral infection (like influenza or COVID-19) is suspected or diagnosed alongside EVALI, antiviral medications may be prescribed.

7. Discontinuing Vaping

• The most important part of treatment is discontinuing the use of e-cigarettes or vaping products. Patients should be advised not to resume vaping after recovery, as continued use can worsen symptoms and lead to further lung damage.

8. Follow-up Care

• Follow-up visits with healthcare providers are important to monitor recovery, especially lung function. In some cases, patients may need pulmonary rehabilitation or further imaging to assess lung recovery.

9. Psychological Support

• Since vaping is often linked to addiction, providing psychological support and counseling may help patients quit vaping and avoid relapse.

The reversibility of EVALI

The reversibility of EVALI (E-cigarette or Vaping Product Use-Associated Lung Injury) depends on the severity of the injury, how quickly treatment is initiated, and whether the individual discontinues vaping.

In cases of mild to moderate EVALI:

• Reversibility is possible with timely intervention, including the discontinuation of vaping and the administration of treatments like corticosteroids. Many patients experience significant improvement in lung function within weeks to months after they stop vaping and receive appropriate medical care.
• Recovery: Individuals with mild to moderate cases may recover fully, but follow-up care and monitoring are necessary to ensure that there is no long-term damage.

In cases of severe EVALI:

• Partial recovery may occur, but irreversible damage is possible, especially if the injury to the lungs is extensive. Severe cases may lead to lasting lung damage, respiratory issues, or even long-term disability, particularly if mechanical ventilation or other life-support measures are required.
• Permanent damage: For those with severe symptoms or complications, such as respiratory failure, the lungs may not return to normal function, and patients may experience long-term health issues like decreased lung capacity or chronic respiratory problems.

While mild cases of EVALI can often be reversed with appropriate treatment and discontinuation of vaping, severe cases may result in permanent lung damage. Early intervention is key to improving the chances of full recovery, which is why stopping vaping as soon as symptoms arise is crucial for reducing long-term health risks.

How to Prevent EVALI

Preventing EVALI (E-cigarette or Vaping Product Use-Associated Lung Injury) primarily involves reducing or eliminating the use of e-cigarettes and vaping products. Here are key strategies to help prevent EVALI:

1. Avoid Vaping Products

• The most effective way to prevent EVALI is to avoid using e-cigarettes and vaping products altogether, especially those that contain THC or are obtained from unregulated sources. Even nicotine-only e-cigarettes can have potential health risks.

2. Be Cautious with THC Products

• Avoid vaping THC (tetrahydrocannabinol)-containing products, particularly those purchased from unregulated or illicit markets. These products are more likely to contain harmful additives, like vitamin E acetate, which has been strongly linked to EVALI cases.
• If choosing to use THC products, it's important to ensure they are from reputable, regulated sources with verified ingredients.

3. Choose Regulated, Verified Products

• If you do use e-cigarettes, only purchase products from reliable and regulated sources. Reputable brands will adhere to safety and quality standards, reducing the likelihood of harmful additives.
• Be cautious about buying from unregulated or "black market" sources, as these are more likely to contain dangerous contaminants.

4. Avoid Modifying or Using Homemade Vaping Products

• Do not use modified or homemade vaping products, as these can introduce unsafe substances into the aerosol. Modifying e-cigarettes or using homemade liquids increases the risk of harmful exposure.

5. Stop Vaping if You Experience Symptoms

• If you experience any respiratory symptoms (e.g., coughing, shortness of breath, chest pain, fatigue) or feel unwell after vaping, stop immediately and seek medical advice. Early intervention can help prevent more serious injuries.

6. Educate Yourself and Others

• Stay informed about the risks of e-cigarettes and vaping, and educate others, especially young people, about the potential dangers of using these products. Public health campaigns, like those offered by health organizations, can help raise awareness of EVALI.

7. Support Quitting Programs

• If you or someone you know is trying to quit smoking or vaping, seek support through quit smoking programs or counseling services. Support services, such as Quitline in Australia or other cessation programs, offer resources and guidance for successfully quitting.

8. Advocate for Regulation

• Support and advocate for stronger regulation of e-cigarettes and vaping products to ensure they meet safety standards. This can help reduce the presence of harmful chemicals in the market and protect consumers from potentially harmful substances.

Final Thoughts on EVALI

EVALI (E-cigarette or Vaping Product Use-Associated Lung Injury) is a serious and preventable health condition linked to the use of e-cigarettes and vaping products, particularly those containing THC or obtained from unregulated sources. While many cases can be treated with early intervention, severe cases can lead to lasting lung damage or even death. The key to preventing EVALI lies in avoiding vaping, especially unregulated or illicit products, and staying informed about the potential risks associated with e-cigarettes.

For those who use e-cigarettes, it's crucial to choose products from reputable sources, avoid modifying vaping devices, and seek medical attention immediately if any symptoms of lung injury arise. Quitting vaping and seeking support for cessation can significantly reduce the risk of developing EVALI and other long-term respiratory issues.

Ultimately, public awareness, responsible use, and regulation of vaping products are essential to reducing the incidence of EVALI and protecting lung health. If you're considering quitting vaping, many support systems and programs are available to help you make the transition to a healthier, smoke-free life.

TLDR

References:

• Centers for Disease Control and Prevention (CDC) – EVALI
• U.S. Food and Drug Administration (FDA) - Vaping and EVALI
• Australian Government Department of Health – Vaping and EVALI
• American Lung Association – EVALI and Lung Health
• National Institute on Drug Abuse (NIDA) – E-cigarettes and Vaping

Disclaimer

This medical blog provides general information and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult with your regular doctor for specific medical concerns. The content is based on the knowledge available at the time of publication and may change. While we strive for accuracy, we make no warranties regarding completeness or reliability. Use the information at your own risk. Links to other websites are provided for convenience and do not imply endorsement. The views expressed are those of the authors and not necessarily representative of any institutions.